Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00302731Phase 2Terminated

Bioidentical 'Natural' Hormone Evaluation in Early Menopause

Role: lead

NCT01364805Phase 1Completed

New Treatment Option for Pancreatic Cancer

Role: lead

NCT00228319Phase 1Completed

Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants

Role: lead

NCT00284427Phase 2Completed

Safety of Antioxidants During GYN Cancer Care

Role: lead

All 4 trials loaded